tiprankstipranks

Dianthus initiated with an Outperform at Baird

Baird initiated coverage of Dianthus with an Outperform rating and $58 price target. Lead agent DNTH103 is entering Phase 2 trials for three autoimmune neuromuscular diseases – generalized myasthenia gravis, or gMG, multifocal motor neuropathy, or MMN, and chronic inflammatory demyelinating polyneuropathy, or CIDP – notes the analyst. The firm believes complement inhibitors will be a leading drug class for each of these three indications and believe DNTH103 is well positioned to become the “leading complement inhibitor for each indication.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue